Ge Long Hui·2026-03-17 23:12Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed financial performance with a decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion yuan, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion yuan, showing a substantial year-on-year increase of 163.80% [1] - Total profit was reported at 1.509 billion yuan, which is a year-on-year growth of 162.22% [1] - The net profit attributable to shareholders was 1.136 billion yuan, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on net assets rose by 2.59 percentage points compared to the previous year [1] Factors Influencing Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million yuan year-on-year [1] - Additionally, adjustments in store operations led to a decline in fixed costs such as labor and rent [1]